CoChat

The DOI matches its Crossref record; 671 of the 685 references it cites were found in a registry or an index, and 14 are not checked yet.

From Polyphenols to Prodrugs: Bridging the Blood–Brain Barrier with Nanomedicine and Neurotherapeutics

Open access
Tanaka, Masaru, Araujo, Adriano Cressoni, Valenti, Vítor Engrácia, Guiguer, Elen Landgraf, Catharin, Vitor Cavallari Strozze, Gualhardi, Cristiano Machado, de Souza Bastos Mazuqueli Pereira, Eliana, de Alvares Goulart, Ricardo, de Argolo Haber, Rafael Santos, de Carvalho, Atonelly Cassio Alves, Barbalho, Sandra Maria · 2026 · International Journal of Molecular Sciences

Abstract

Central nervous system disorders drive disability, yet many neuroactive candidates fail because the brain is a hard compartment to dose. Plant-derived molecules spanning polyphenols, alkaloids, terpenoids, and cannabinoids are attractive because their pleiotropic actions can engage oxidative stress, neuroinflammation, and circuit dysfunction. In practice, the blood–brain barrier (BBB) restricts most native phytochemicals through tight-junction selectivity, rapid metabolism, low solubility, and transporter-mediated efflux. Key gaps include poor standardization of exposure metrics, limited human-relevant BBB models, and few head-to-head studies that compare delivery platforms on the same payload and outcome. This review tackles the mismatch between mechanistic promise and reliable brain exposure that stalls translation. The objectives are to link phytochemical liabilities to enabling strategies in nanomedicine, alternative routes, and transporter-targeted prodrugs, and to propose decision-grade endpoints for translation. We synthesize evidence on BBB transport logic, nanocarrier families, targeting ligands, intranasal delivery, focused ultrasound-mediated opening, and prodrug approaches that hijack influx transporters, while foregrounding safety and chemistry, manufacturing, and controls (CMC) constraints. Here we highlight that effective neurotherapeutics emerge when chemistry, carrier, route, and measurement are co-designed rather than optimized in isolation. This framework can guide platform selection, de-risk first in-human studies, and sharpen trial endpoints. More broadly, it offers a transferable playbook for barrier-limited drug development across neurology, psychiatry, and oncology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms27052370

Cites

671 of 685 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Blood–brain barrier (BBB) transport routes and where delivery platforms intervene: passive limits, engineered influx, and efflux ceilings. The schematic summarizes dominant BBB transport routes relevant to phytochemicals and highlights where delivery platforms intervene. At an intact BBB, paracellular diffusion across tight junctions is negligible and disease-dependent; controlled opening is best treated as a localized modulation strategy (e.g., focused ultrasound (FUS) with microbubbles) rather than a baseline assumption. Transcellular passive diffusion depends on size, polarity, hydrogen bonding, and lipophilicity, but apparent permeability is often capped by metabolism and active efflux. ABC transporters—P-gp, BCRP, MRPs—frequently set the ceiling for unbound brain exposure, motivating efflux-evading prodrugs, stealth/corona control for nanocarriers, and early efflux-liability screening. For polar phytochemicals, carrier-mediated transport (CMT) via GLUT1, LAT1, and MCT1 enables engineered influx using nutrient-mimetic promoieties, requiring Km/VMAX-aware design and brain-selective cleavage. For larger cargos, receptor-mediated transcytosis (RMT) via TfR and LRP1 supports ligand-decorated nanocarriers, but demands an affinity “sweet spot” to avoid endothelial sequestration and lysosomal routing. Adsorptive/CPP uptake can boost entry yet trades specificity for off-target risk; charge-switchable or stimulus-unmasked coatings can mitigate this. Intranasal delivery provides a complementary bypass for suitable payloads. ABC, ATP-binding cassette; BBB, blood–brain barrier; BCRP, breast cancer resistance protein; CMT, carrier-mediated transport; CPP, cell-penetrating peptide; FUS, focused ultrasound; GLUT1, glucose transporter 1; Km, Michaelis constant; LAT1, L-type amino acid transporter 1; LRP1, low-density lipoprotein receptor-related protein 1; MCT1, monocarboxylate transporter 1; MRPs, multidrug resistance-associated proteins; P-gp, P-glycoprotein; RMT, receptor-mediated transcytosis; TfR, transferrin receptor; VMAX, maximum transport rate.
Figure 1 Blood–brain barrier (BBB) transport routes and where delivery platforms intervene: passive limits, engineered influx, and efflux ceilings. The schematic summarizes dominant BBB transport routes relevant to phytochemicals and highlights where delivery platforms intervene. At an intact BBB, paracellular diffusion across tight junctions is negligible and disease-dependent; controlled opening is best treated as a localized modulation strategy (e.g., focused ultrasound (FUS) with microbubbles) rather than a baseline assumption. Transcellular passive diffusion depends on size, polarity, hydrogen bonding, and lipophilicity, but apparent permeability is often capped by metabolism and active efflux. ABC transporters—P-gp, BCRP, MRPs—frequently set the ceiling for unbound brain exposure, motivating efflux-evading prodrugs, stealth/corona control for nanocarriers, and early efflux-liability screening. For polar phytochemicals, carrier-mediated transport (CMT) via GLUT1, LAT1, and MCT1 enables engineered influx using nutrient-mimetic promoieties, requiring Km/VMAX-aware design and brain-selective cleavage. For larger cargos, receptor-mediated transcytosis (RMT) via TfR and LRP1 supports ligand-decorated nanocarriers, but demands an affinity “sweet spot” to avoid endothelial sequestration and lysosomal routing. Adsorptive/CPP uptake can boost entry yet trades specificity for off-target risk; charge-switchable or stimulus-unmasked coatings can mitigate this. Intranasal delivery provides a complementary bypass for suitable payloads. ABC, ATP-binding cassette; BBB, blood–brain barrier; BCRP, breast cancer resistance protein; CMT, carrier-mediated transport; CPP, cell-penetrating peptide; FUS, focused ultrasound; GLUT1, glucose transporter 1; Km, Michaelis constant; LAT1, L-type amino acid transporter 1; LRP1, low-density lipoprotein receptor-related protein 1; MCT1, monocarboxylate transporter 1; MRPs, multidrug resistance-associated proteins; P-gp, P-glycoprotein; RMT, receptor-mediated transcytosis; TfR, transferrin receptor; VMAX, maximum transport rate.CC BY · PubMed Central
Figure 2 Decision tree for selecting CNS delivery strategies by payload liabilities and clinical context. The schematic provides a pragmatic decision tree to match a CNS payload to the most efficient delivery strategy. The workflow begins with dominant liabilities: (i) solubility/dissolution limitation, (ii) efflux liability (e.g., P-gp/BCRP/MRPs), and (iii) chemical or metabolic instability. Solubility-driven failure routes first to formulation solutions (solubilizing vehicles, lipid systems, polymeric nanoparticles, mucoadhesive/intranasal formats when appropriate). Predominant efflux liability routes to prodrug design (efflux-evading promoieties or transporter-hijacking approaches such as GLUT1/LAT1/MCT1) and/or carrier shielding/targeting (stealth/corona control; RMT ligands such as TfR/LRP1). Instability-driven failure routes to protective encapsulation or stability-optimized prodrugs with controlled release. Clinical context modifiers (need for rapid onset, diffuse vs. focal pathology, and tolerability constraints) direct selection of route (e.g., intranasal bypass) or focused ultrasound (FUS) + microbubbles for localized BBB modulation. Each terminal node specifies decision-grade endpoints: brain exposure (AUC, Kp,brain, Kp,uu), target engagement, safety margin, and CMC scalability. AUC, area under the curve; BBB, blood–brain barrier; BCRP, breast cancer resistance protein; CMC, chemistry, manufacturing, and controls; CNS, central nervous system; FUS, focused ultrasound; GLUT1, glucose transporter 1; Kp,brain, brain-to-plasma partition coefficient; Kp,uu, unbound brain-to-plasma partition coefficient; LAT1, L-type amino acid transporter 1; MCT1, monocarboxylate transporter 1; MRPs, multidrug resistance-associated proteins; P-gp, P-glycoprotein; RMT, receptor-mediated transcytosis; TfR, transferrin receptor; LRP1, low-density lipoprotein receptor-related protein 1.
Figure 2 Decision tree for selecting CNS delivery strategies by payload liabilities and clinical context. The schematic provides a pragmatic decision tree to match a CNS payload to the most efficient delivery strategy. The workflow begins with dominant liabilities: (i) solubility/dissolution limitation, (ii) efflux liability (e.g., P-gp/BCRP/MRPs), and (iii) chemical or metabolic instability. Solubility-driven failure routes first to formulation solutions (solubilizing vehicles, lipid systems, polymeric nanoparticles, mucoadhesive/intranasal formats when appropriate). Predominant efflux liability routes to prodrug design (efflux-evading promoieties or transporter-hijacking approaches such as GLUT1/LAT1/MCT1) and/or carrier shielding/targeting (stealth/corona control; RMT ligands such as TfR/LRP1). Instability-driven failure routes to protective encapsulation or stability-optimized prodrugs with controlled release. Clinical context modifiers (need for rapid onset, diffuse vs. focal pathology, and tolerability constraints) direct selection of route (e.g., intranasal bypass) or focused ultrasound (FUS) + microbubbles for localized BBB modulation. Each terminal node specifies decision-grade endpoints: brain exposure (AUC, Kp,brain, Kp,uu), target engagement, safety margin, and CMC scalability. AUC, area under the curve; BBB, blood–brain barrier; BCRP, breast cancer resistance protein; CMC, chemistry, manufacturing, and controls; CNS, central nervous system; FUS, focused ultrasound; GLUT1, glucose transporter 1; Kp,brain, brain-to-plasma partition coefficient; Kp,uu, unbound brain-to-plasma partition coefficient; LAT1, L-type amino acid transporter 1; MCT1, monocarboxylate transporter 1; MRPs, multidrug resistance-associated proteins; P-gp, P-glycoprotein; RMT, receptor-mediated transcytosis; TfR, transferrin receptor; LRP1, low-density lipoprotein receptor-related protein 1.CC BY · PubMed Central
Figure 3 Focused ultrasound (FUS) delivery paradigm: acoustic control, microbubble cavitation, transient blood–brain barrier (BBB) opening, and safety monitoring. The schematic summarizes the focused ultrasound (FUS)–microbubble paradigm for transient, spatially targeted BBB modulation to enable CNS delivery. (A) Acoustic parameters (frequency, peak negative pressure, pulse length, pulse repetition frequency, duty cycle, and sonication duration) set the cavitation regime and therefore the balance between efficacy and risk. (B) Microbubble dynamics span a spectrum from no response (insufficient opening) to stable cavitation (desired oscillation that increases permeability) and inertial cavitation (collapse associated with vascular damage risk). These regimes are inferred in real time using acoustic emissions and passive cavitation detection to support parameter adjustment and stop rules. (C) BBB opening window is depicted as a reversible permeability increase (minutes–hours) during which small molecules, prodrugs, and nanocarriers can cross the endothelium; closure restores barrier integrity. (D) Safety monitoring includes image-guided targeting (MRI), confirmation of opening (contrast-enhanced MRI), surveillance for edema or microhemorrhage, and temperature/physiological checks where relevant. Together, the framework links controllable acoustic inputs to microbubble behavior, delivery timing, and verification steps required for reproducible, trial-grade BBB opening. BBB, blood–brain barrier; CNS, central nervous system; FUS, focused ultrasound; MRI, magnetic resonance imaging.
Figure 3 Focused ultrasound (FUS) delivery paradigm: acoustic control, microbubble cavitation, transient blood–brain barrier (BBB) opening, and safety monitoring. The schematic summarizes the focused ultrasound (FUS)–microbubble paradigm for transient, spatially targeted BBB modulation to enable CNS delivery. (A) Acoustic parameters (frequency, peak negative pressure, pulse length, pulse repetition frequency, duty cycle, and sonication duration) set the cavitation regime and therefore the balance between efficacy and risk. (B) Microbubble dynamics span a spectrum from no response (insufficient opening) to stable cavitation (desired oscillation that increases permeability) and inertial cavitation (collapse associated with vascular damage risk). These regimes are inferred in real time using acoustic emissions and passive cavitation detection to support parameter adjustment and stop rules. (C) BBB opening window is depicted as a reversible permeability increase (minutes–hours) during which small molecules, prodrugs, and nanocarriers can cross the endothelium; closure restores barrier integrity. (D) Safety monitoring includes image-guided targeting (MRI), confirmation of opening (contrast-enhanced MRI), surveillance for edema or microhemorrhage, and temperature/physiological checks where relevant. Together, the framework links controllable acoustic inputs to microbubble behavior, delivery timing, and verification steps required for reproducible, trial-grade BBB opening. BBB, blood–brain barrier; CNS, central nervous system; FUS, focused ultrasound; MRI, magnetic resonance imaging.CC BY · PubMed Central
Figure 4 Roadmap timeline for brain delivery platforms: short-term deployables versus long-term maturation, with validation gates and dependencies. Gantt-style bands summarize expected maturation windows for CNS delivery strategies and the dependencies that determine whether programs advance from feasibility to translation. Short-term (2–4 years) tracks emphasize “deployable” options with the clearest CMC and endpoint pathways: ligand-targeted PLGA nanoparticles/liposomes (e.g., transferrin or RVG; resveratrol/curcumin, including dual loading) gated by reproducible size/PDI, loading, and stability under scalable unit operations; intranasal mucoadhesive nanoemulsions/nanoemulgels (chitosan or thermo/in situ gels) gated by droplet-size distribution, rheology, spray plume metrics, preservative compatibility, and tolerability plus PK surrogates (CSF or imaging-rich substudies where justified); LAT1-anchored prodrugs gated by LAT1 affinity, bioconversion kinetics, intrabrain distribution, and target engagement in neurons/glia; and focused ultrasound-assisted regional delivery gated by imaging-confirmed BBB opening, local PK confirmation, and regulator-recognized safety monitoring. Longer-term (5–10+ years) bands capture exosome mimetics/hybrid vesicles (GMP scale-up and heterogeneity control), AI-designed multi-target nano–prodrugs (auditable datasets and prospective validation), remote-triggered release (dosimetry and repeat-use safety standards), and BBB “digital twins” integrating PBPK/PKPD with real-time TEER and registries. AI, artificial intelligence; BBB, blood–brain barrier; CMC, chemistry, manufacturing, and controls; CNS, central nervous system; CSF, cerebrospinal fluid; GMP, good manufacturing practice; LAT1, large neutral amino acid transporter 1; PBPK, physiologically based pharmacokinetic; PDI, polydispersity index; PK, pharmacokinetics; PKPD, pharmacokinetic–pharmacodynamic; PLGA, poly(lactic-co-glycolic acid); RVG, rabies virus glycoprotein; TEER, transendothelial electrical resistance.
Figure 4 Roadmap timeline for brain delivery platforms: short-term deployables versus long-term maturation, with validation gates and dependencies. Gantt-style bands summarize expected maturation windows for CNS delivery strategies and the dependencies that determine whether programs advance from feasibility to translation. Short-term (2–4 years) tracks emphasize “deployable” options with the clearest CMC and endpoint pathways: ligand-targeted PLGA nanoparticles/liposomes (e.g., transferrin or RVG; resveratrol/curcumin, including dual loading) gated by reproducible size/PDI, loading, and stability under scalable unit operations; intranasal mucoadhesive nanoemulsions/nanoemulgels (chitosan or thermo/in situ gels) gated by droplet-size distribution, rheology, spray plume metrics, preservative compatibility, and tolerability plus PK surrogates (CSF or imaging-rich substudies where justified); LAT1-anchored prodrugs gated by LAT1 affinity, bioconversion kinetics, intrabrain distribution, and target engagement in neurons/glia; and focused ultrasound-assisted regional delivery gated by imaging-confirmed BBB opening, local PK confirmation, and regulator-recognized safety monitoring. Longer-term (5–10+ years) bands capture exosome mimetics/hybrid vesicles (GMP scale-up and heterogeneity control), AI-designed multi-target nano–prodrugs (auditable datasets and prospective validation), remote-triggered release (dosimetry and repeat-use safety standards), and BBB “digital twins” integrating PBPK/PKPD with real-time TEER and registries. AI, artificial intelligence; BBB, blood–brain barrier; CMC, chemistry, manufacturing, and controls; CNS, central nervous system; CSF, cerebrospinal fluid; GMP, good manufacturing practice; LAT1, large neutral amino acid transporter 1; PBPK, physiologically based pharmacokinetic; PDI, polydispersity index; PK, pharmacokinetics; PKPD, pharmacokinetic–pharmacodynamic; PLGA, poly(lactic-co-glycolic acid); RVG, rabies virus glycoprotein; TEER, transendothelial electrical resistance.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 654 references

Cited by

See all 18

Metadata

Authors
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., & Barbalho, S. M.
Affiliations
  • University of Szeged (HU)
  • Department of Biochemistry and Pharmacology, School of Medicine, Faculdade de Medicina de Marília, Universidade de Marília (UNIMAR), Marilia 17525-902, SP, Brazil
  • Universidade Estadual Paulista (Unesp) (BR)
  • Graduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marilia 17525-902, SP, Brazil
Corresponding author
  • Tanaka, Masaru
  • Barbalho, Sandra Maria
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2026-03-03
Volume
27
Issue
5
Pages
2370
ISSN
1422-0067 (ISSN-L)
OpenAlex
W7133487442
Cited by
13
References
654
Citations by year
2026: 13
FWCI
9.92
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
HUN-REN Hungarian Research Network (-)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
blood-brain barrier, polyphenols, prodrugs, phytochemicals, nanocarriers, neurotherapeutics, intranasal drug delivery, focused ultrasound, BBB transporters, tight junctions, brain exposure, drug delivery routes, neuroinflammation, oxidative stress
MeSH terms
Animals, Blood-Brain Barrier, Central Nervous System Diseases, Humans, Prodrugs, Drug Delivery Systems, Nanomedicine, Polyphenols

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: From Polyphenols to Prodrugs: Bridging the Blood–Brain Barrier with Nanomedicine and Neurotherapeutics. https://app.cochat.ai/papers/10.3390/ijms27052370
The paper
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., & Barbalho, S. M. (2026). From Polyphenols to Prodrugs: Bridging the Blood–Brain Barrier with Nanomedicine and Neurotherapeutics. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27052370

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.